Global juvenile idiopathic arthritis diagnostic market demand is anticipated to be valued at US$ 5,810.5 Million in 2022, forecast to grow at a CAGR of 4.0% to be valued at US$ 8,600.7 Million from 2022 to 2032. Growth is attributed to the increasing prevalence of diseases such as Oligoarthritis, Polyarticular arthritis, rheumatoid factor negative, Psoriatic arthritis, and Enthesitis-related arthritis.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 5,795.5 Million |
| Expected Market Value (2022) | US$ 5,810.5 Million |
| Anticipated Forecast Value (2032) | US$ 8,600.7 Million |
| Projected Growth Rate (2022 to 2032) | 4.0% CAGR |
Juvenile idiopathic arthritis is a disease that causes pain and inflammation in joints with the common symptom of musculoskeletal pain. Juvenile idiopathic arthritis or juvenile rheumatoid arthritis is the common inflammatory arthritis of childhood and mostly affects the under 17 age group children.
The USA is considered to be a highly lucrative market for juvenile idiopathic arthritis diagnosis due to the presence of the technologically advanced healthcare and pharmaceutical industry.
Government initiatives regarding awareness of Juvenile Idiopathic Arthritis disease are likely to drive the growth of the Juvenile Idiopathic Arthritis Diagnostics market. Additionally, the increasing incidence of chronic arthritis is expected to boost the juvenile idiopathic arthritis diagnostic market over the forecast period. Rising awareness among the general population and a better understanding of these drugs is expected to drive the juvenile idiopathic arthritis diagnostic market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The juvenile idiopathic arthritis diagnostic market is expected to grow in the coming forecast period for increasing demand for more effective drugs and better medical facilities. The major factor that will propel the growth of the juvenile idiopathic arthritis diagnostic market is the rising focus by the manufacturer to develop tests creating huge opportunities for patients.
The growth of the healthcare industry is expected to be one of the primary factors driving the diagnostic lab market which in turn is expected to augment the demand for the Juvenile Idiopathic Arthritis diagnostic market over the next few years. In addition, rapid Research and Development activities are expected to fuel the demand for the market over the forecasting period. The research laboratory is expected to accrue significant benefits to the global juvenile idiopathic arthritis diagnostic market.
Although the juvenile idiopathic arthritis diagnostic market has numerous end-uses, there are numerous obstacles likely to pose a challenge to market growth. The high cost of treatment of juvenile arthritis is expected to hinder the growth of the juvenile idiopathic arthritis diagnostic market.
Lack of awareness and less expenditure spent on healthcare and research may restrain the growth of the Juvenile Idiopathic Arthritis Diagnostics market. Difficult diagnostic procedures and limited availability of tests may restrain the growth of the Juvenile Idiopathic Arthritis Diagnostics market in the forecasting period.
Principal Consultant
North America has the largest market for juvenile idiopathic arthritis diagnostics and the trend is expected to continue into the forecast period owing to a rapid increase in healthcare expenditure and increasing research and development activities in the region. The region is forecast to surge at over 3.7% CAGR from 2022 to 2032.
The rising prevalence of chronic arthritis is expected to drive the growth of the juvenile idiopathic Arthritis Diagnostic Market over the forecast period. Increasing awareness among the general population, the significance of this condition, and a better understanding of these drugs are expected to drive the juvenile idiopathic arthritis diagnostic market during the forecast period.
According to Future Market Insights, Europe is expected to provide immense growth opportunities for the juvenile idiopathic arthritis diagnostic market. Higher spending on healthcare expenditure is keeping sales of the juvenile idiopathic arthritis diagnostic market afloat across the United Kingdom.
Increasing research and development activities, the development of drugs for the treatment of polyarticular juvenile idiopathic arthritis, and higher demand from the end-users provide growth opportunities to the market in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key participants present in the global juvenile idiopathic arthritis diagnostic market include Johnson & Johnson Services, Inc., Novartis International AG, Bristol-Myers Squibb, Zydus Cadila, Genentech, Inc., and Latona Life Sciences among others.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as A Johnson & Johnson Services, Inc., and Novartis International AG account for a considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4.0% from 2022 to 2032 |
| Market Value in 2022 | US$ 5,810.5 Million |
| Market Value in 2032 | US$ 8,600.7 Million |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global juvenile idiopathic arthritis diagnostic market to expand at a 4.0% value CAGR by 2032
North America is expected to be the most opportunistic juvenile idiopathic arthritis diagnostic market, expanding at a 3.7% CAGR
Johnson & Johnson Services, Inc., Novartis International AG, Bristol-Myers Squibb, and Zydus Cadila are some prominent juvenile idiopathic arthritis diagnostic market manufacturers
1. Executive Summary | Juvenile Idiopathic Arthritis Diagnostic Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Investment Feasibility Matrix 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Indication 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2022 to 2032 5.3.1. Blood Tests 5.3.2. ESR 5.3.3. C-reactive Protein 5.3.4. Anti-nuclear Antibody 5.3.5. Rheumatoid Factor 5.3.6. Cyclic Citrullinated Peptide (CCP) 5.3.7. HLA-B27 Tests 5.3.8. Imaging Scans 5.3.9. X-rays 5.3.10. MRI 5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Disease Indication, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032 6.3.1. Hospitals 6.3.2. Research Laboratories 6.3.3. Diagnostic Laboratories 6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Disease Indication 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Disease Indication 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Disease Indication 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease Indication 9.3.3. By End User 9.4. Key Takeaways 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. Italy 10.2.1.3. France 10.2.1.4. United Kingdom 10.2.1.5. Russia 10.2.1.6. BENELUX 10.2.1.7. Rest of Europe 10.2.2. By Disease Indication 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Indication 10.3.3. By End User 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Rest of Asia Pacific 11.2.2. By Disease Indication 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Indication 11.3.3. By End User 11.4. Key Takeaways 12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Turkey 12.2.1.4. Rest of Middle East and Africa 12.2.2. By Disease Indication 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Indication 12.3.3. By End User 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. USA 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2021 13.1.2.1. By Disease Indication 13.1.2.2. By End User 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2021 13.2.2.1. By Disease Indication 13.2.2.2. By End User 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2021 13.3.2.1. By Disease Indication 13.3.2.2. By End User 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2021 13.4.2.1. By Disease Indication 13.4.2.2. By End User 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2021 13.5.2.1. By Disease Indication 13.5.2.2. By End User 13.6. Italy 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2021 13.6.2.1. By Disease Indication 13.6.2.2. By End User 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2021 13.7.2.1. By Disease Indication 13.7.2.2. By End User 13.8. United Kingdom 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2021 13.8.2.1. By Disease Indication 13.8.2.2. By End User 13.9. Russia 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2021 13.9.2.1. By Disease Indication 13.9.2.2. By End User 13.10. BENELUX 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2021 13.10.2.1. By Disease Indication 13.10.2.2. By End User 13.11. China 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2021 13.11.2.1. By Disease Indication 13.11.2.2. By End User 13.12. Japan 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2021 13.12.2.1. By Disease Indication 13.12.2.2. By End User 13.13. South Korea 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2021 13.13.2.1. By Disease Indication 13.13.2.2. By End User 13.14. GCC Countries 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2021 13.14.2.1. By Disease Indication 13.14.2.2. By End User 13.15. South Africa 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2021 13.15.2.1. By Disease Indication 13.15.2.2. By End User 13.16. Turkey 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2021 13.16.2.1. By Disease Indication 13.16.2.2. By End User 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Disease Indication 14.3.3. By End User 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Johnson & Johnson Services 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Novartis International AG 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Bristol-Myers Squibb 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Zydus Cadila 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Genentech 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Latona Life Sciences 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Juvenile Idiopathic Arthritis Diagnostic Market
